HbA1c differences between intensively and conventionally treated patients in major clinical trials, with baseline to endpoint HbA1c level in type 1 diabetes.

Slides:

Advertisements

Similar presentations

Management of Diabetes Treat to Target Approach (A1c

Advertisements

UKPDS Paper 35 Slides © University of Oxford Diabetes Trials Unit

Diabetes Mellitus Type 2

Diabetic Microvascular Disease: The Role of Glycemic Control and the Impact on Public Health Robert E. Ratner, MD MedStar Research Institute Georgetown.

Blood glucose: is lower better for diabetic patients?

Changing Values. When does 6.5 = 48? Is this a well controlled diabetic? DateHbA1c mmol/mol 23/04/ /11/ /01/ /11/ /09/

1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.

ERECTILE DYSFUNCTION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.

Date of download: 5/28/2016 From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved.

Diabetic Retinopathy Histology Pathogenesis online folderonline folder 14 years of diabetes with medicocre control Longer.

Volume 352, Issue 9131, Pages (September 1998)

The American College of Cardiology Presented by Dr. Nikolaus Marx

Figure 1. Consort flow diagram.

Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole Truth, and Nothing But the Truth.

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2008 American Medical Association. All rights reserved.

Copyright © 2017 American Academy of Pediatrics.

HbA1c as a Marker of Glycaemic Control in Diabetes Care

Diabetic Dyslipidemia in Practice

Macrovascular Complications Microvascular Complications

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

366 میلیون نفر در جهان مبتلا به دیابت هستند.

Hemoglobin A1c Targets for Glycemic Controls

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Modulation of the intensiveness of glucose lowering in type 2 diabetes

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Clinical Application of New CV Outcomes Data

A: Box plot comparing the average changes in HbA1c between surgery and medical/lifestyle treatments in the first reports of the 11 RCTs published to date.

Figure 5 Risk factor control in the intensive treatment group

The risk of DR progression as related to mean HbA1c during DCCT

A: Kaplan-Meier estimate of time to first LLA

Novel Approaches to T1D Management

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Aspirin and Cardioprevention in 2018

Residual CV Risk in Patients With Dyslipidemia and Stable CAD

Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.

Pharmacotherapy for Diabetic Coronary Disease:

Dual SGLT1/SGLT2 Inhibition in T1D

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Hazard ratios for the primary end point by subgroup of achieved LDL cholesterol (adjusted for age, sex, baseline calculated LDL cholesterol, diabetes,

Side-by-side comparison of change in A1C with canagliflozin versus DPP-4 inhibitors in randomized clinical trials and the real-world study. *Data are LS.

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Are All Novel Insulins Proven to Be Equally Safe?

Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.

The American College of Cardiology Presented by Dr. Nikolaus Marx

Association between antibiotic purchases and glycated hemoglobin (HbA1c) values in patients with and without diabetic nephropathy. Association between.

Statin Selection in Patients With Pre-Diabetes: Case Considerations

New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Observed RW, modeled, and published trial estimates of HbA1c change from baseline. Observed RW, modeled, and published trial estimates of HbA1c change.

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or.

This figure illustrates the importance of heart failure consideration in primary endpoint trials with hypoglycemic agents. This figure illustrates the.

Trajectories over the 9 years of follow-up of HbA1c in all participants (n = 4,080 at baseline), stratified by the presence of a family history of diabetes,

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

A1C at baseline and each maintenance month by treatment in the GEMINI trial, including the modified intention-to-treat population. A1C at baseline and.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

Biopsies of the vaccination site were obtained 48 h after the first vaccination. Biopsies of the vaccination site were obtained 48 h after the first vaccination.

The Power of As-Treated Analyses

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Translating Data From Trial to Practice

Presentation transcript:

HbA1c differences between intensively and conventionally treated patients in major clinical trials, with baseline to endpoint HbA1c level in type 1 diabetes (DCCT, SDIS) and type 2 diabetes (UKPDS, Kumamoto). HbA1c differences between intensively and conventionally treated patients in major clinical trials, with baseline to endpoint HbA1c level in type 1 diabetes (DCCT, SDIS) and type 2 diabetes (UKPDS, Kumamoto). Mohammad Saleh, and George Grunberger Clin Diabetes 2001;19:161-167 ©2001 by American Diabetes Association